Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

NIH’s decision to cut what it pays universities and other entities for indirect costs associated with scientific research ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 11.71%, which has investors questioning if this is right ...

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a ...

The president announced a major AI investment project, which Oracle Chairman Larry Ellison said could be used to cure cancer.

mRNA vaccines prompt the body’s cells to produce ... controlled chronic health conditions), and to have had no recent history of gastrointestinal illness, among other criteria.

It's therefore worth looking at Moderna's earnings history below. Of course, the future is what really matters. NasdaqGS:MRNA Earnings and Revenue Growth January 22nd 2025 Investors should note ...